Infinity

Transcatheter mitral valve technology delivered via 14 French catheters. Competing in a $25 billion market where recent exits had near $1billion valuations.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Denver, CO, US
  • Currency USD
  • Founded June 2015
  • Employees 2

Company Summary

Transcatheter Mitral Valve Replacement (TMVR) is the next big thing after TAVR (aortic valve). This summer, companies that have achieved First in Man have enjoyed acquisitions ranging from over $200 million to nearly $1 billion. But the current devices are too bulky and need introducers as large as 34 French. Our technology enables the TMVR components to be delivered sequentially, with introducers as small as 14 French, a huge leap over the competition.

Team

  • Ivan Vesely
    Founder / CEO

    Dr. Vesely is the Founder of the company, and its current CEO and Chief Technology Officer. He is an internationally respected heart valve scientist with previous heart valve company start-up experience. He is the author of 15 issued patents in 10 invention areas, and over 85 publications. At his previous company, he drove the technology through the R&D process, to FIM and European clinical studies, and into the CE Mark approval process.

  • Duane Knight
    CTO

    Mr. Knight, a CPA is a result driven CFO with over 30 years experience in accounting, finance, and operations including CFO of Denver Biomedical, Inc. (sold to Cardinal Health). Extensive public accounting and public and private industry experience, private placement equity, debt and other finance structuring, and IPO’s primarily with early stage medical device enterprises.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free